 Connection
David Moreno to B-Cell Maturation Antigen
This is a "connection" page, showing publications David Moreno has written about B-Cell Maturation Antigen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.595 |
|
|
|
-
Torrecillas-Mayayo V, Oliver-Caldes A, Martínez-Cibrian N, Albiol N, Rodríguez-Lobato LG, Español-Rego M, Ortiz-Maldonado V, Rosiñol L, Tovar N, Navarro-Velasquez S, Charry P, Munárriz D, Mateos JM, Jimenez-Mira C, Moreno DF, Montoro M, Ayora P, Delgado J, Juan M, González-Navarro A, Cibeira MT, Fernández de Larrea C. Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT. Ann Hematol. 2026 May 12; 105(7).
Score: 0.242
-
Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM, Salsench SV, Perez-Amill L, Llobregat H, Carpio Mármol J, Martin-Antonio B, Oliver-Caldes A, Munárriz D, Juan M, Urbano-Ispizua A, Rodríguez-Lobato LG, Fernández de Larrea C. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. J Immunother Cancer. 2026 Mar 03; 14(3).
Score: 0.239
-
Rodríguez-Lobato LG, Cardús O, Mañé-Pujol J, Battram AM, Vaqué-Salsench S, Carpio J, Pérez-Amill L, Calderón H, Martín-Antonio B, Oliver-Caldés A, Lozano E, Moreno DF, Ortiz-Maldonado V, Salas MQ, de Daniel A, Tovar N, Cibeira MT, Rosiñol L, Bladé J, Juan M, Urbano-Ispizua Á, Engel P, Fernández de Larrea C. Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited. Cancer Immunol Res. 2025 Sep 02; 13(9):1374-1390.
Score: 0.231
-
Oliver-Caldes A, Mañe Pujol J, Battram AM, Perez-Amill L, Bachiller M, Calderon H, Castella M, Carpio J, Salsench SV, Tovar N, Cardus O, Urbano-Ispizua A, Moreno DF, Rodríguez-Lobato LG, Lozano E, Rosiñol L, Juan M, Martín-Antonio B, Fernández de Larrea C. TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model. Oncoimmunology. 2025 Dec; 14(1):2529632.
Score: 0.228
-
Zugasti I, Tormo-Ratera M, Oliver-Caldés A, Soler-Perromat JC, González-Calle V, Moreno DF, Cabañas V, López-Muñoz N, Bartolomé-Solanas Á, Español-Rego M, Reguera-Ortega JL, Rosiñol L, López-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EA, Martínez-López J, Mateos MV, Tomás X, Setoain X, Fernández de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
Score: 0.222
-
Battram AM, Mañé-Pujol J, Moreno DF, Oliver-Caldés A, Carpio J, Cardus O, Rodríguez-Lobato LG, Urbano-Ispizua Á, Fernández de Larrea C. Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Adv. 2025 Feb 11; 9(3):627-641.
Score: 0.222
-
Oliver-Caldes A, Español-Rego M, Zabaleta A, González-Calle V, Navarro-Velázquez S, Inogés S, de Cerio AL, Cabañas V, López-Muñoz N, Rodríguez-Otero P, Reguera JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosiñol L, Cid J, Tovar N, Sáez-Peñataro J, López-Parra M, Olesti E, Guillén E, Varea S, Rodríguez-Lobato LG, Battram AM, González MS, Sánchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prósper F, Juan M, Martínez-López J, Moraleda JM, Mateos MV, Urbano-Ispizua Á, Paiva B, Pascal M, Fernández de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15; 30(10):2085-2096.
Score: 0.211
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|